

Attorney Docket No. 09799910-0038

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re P	atent Application of:	. )	Group Art Unit:	_
	William D. EHRINGER	)	Examiner:	
Applic	eation No. 10/627,195	)		
Filed:	July 25, 2003	)		
For:	Wound Healing Compositions and Methods of Use	)		
P.O. B	issioner for Patents ox 1450			

## TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT WITHIN THREE MONTHS OF FILING OR BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. section 1.97(b))

## IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. section 1.97(b).

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. section 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

Transmittal of Information Disclosure Statement Page 2

Each item of information contained in this information disclosure statement was cited in parent application serial number 10/397,048. Copies of these references may be found in parent application serial number 10/397,048.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

Dated: 14 NOV 03

5 L

David E. Crawford, M., Reg. No.

R#spectfully submitted,

Customer No. 26263 314.259.5810

23129837\V-I

15 11 Wall for 17 (4023)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of info unless it contains a valid OMB control no.

a plus sign (+) inside this box ™

Substitu	ate for form	n 1449A/PTO	Comple	te if Known		
		•	Application Number	10/627,195		
41		TION DISCLOSURE	Filing Date	July 25,2003		
STA	TEME	NT BY APPLICANT	First Named Inventor	William D. Ehringer		
			Group Art Unit			
	(us	e as many sheets as necessary)	Examiner Name			
Page 1 o	of 4		Attorney Docket Number	09799910-0038		
		OTHER ITEMS - NON PATE	ENT LITERATURE DOCUME	NTS		
Examiner Initials*	CiteNo.	item (book, magazine, journal, serial, s	nclude name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the tem (book, magazine, journal, serial, symposium, catalog etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	C1	Ainscow, E.K., and Brand, M	I.D. (1999) Top-down co	ntrol analysis of		
		ATP turnover, glycolysis and oxidative phosphorylation in rat hepatocytes.  Eur. J. Biochem. 263:671-685.				
	C2	Arakawa A, Ishiguro S, Ohki	K, Tamai M. (1998) Pre	paration of		
		liposome-encapsulating adenosine triphosphate. Tohuku J Exp Med 184:39-47.				
	C3	Brand, M.D. (1995). Measure	ment of mitochondrial p	roton motive force		
		In Bioenergetics, a Practical A				
		eds. Oxford University Press,				
	C4	Buck, L.T. and P.W. Hochacl				
		and constant membrane poten	tial in hepatocytes: supp	ort for channel	٠	
		arrest," Am. J. Physiol. 265 Regulatory Integrative Comp. Physiol. 34:R1020-1025 (1993).				
	C5	Chien, S., "Metabolic Manage	ement" in Organ Procure	ement and		
		Preservation for Transplanta		4-109, Springer,		
		Landes Bioscience, Austin, TX (1997).				
	C6	Connery, C., G. Hicks, and T.				
		Recovery and Tissue ATP Le		ally Stored Cardiac		
	C7	Explant," Surgical Forum, 41 Eckert, D. and P. Kim, "Mech		mo Eusian seed 14-		
		Inhibition," Annu. Rev. Bioch		uie rusion and its		
	C8	Ehringer, W., D. Belcher, S. V		, "A comparison of		
		the effects of linolenic (18:3 $\Omega$	3) and docosahexaenoic	$(22:6\Omega 3)$ acids on		
		phospholipid bilayers," Chem. Phys. Lipids, 54:79-88 (1990).				
	C9	Ehringer, W., D. Belcher, S. V	Wassall, and W. Stillwell	, "A comparison of		
		$\alpha$ -linolenic acid (18:3 $\Omega$ 3) and $\gamma$ -linolenic acid (18:3 $\Omega$ 6) in				
phosphatidylcholine bilayers," Chem. Phys. Lipids, 57:87-96 (1991).						

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


Under the Pererwork Reduction Act of 1995, no persons are required to respond to a collection of info unless it contains a valid OMB control no.

			Cample	40 15 V	
Substitu	ite for forn	1 1449A/PTO		te if Known	
INIEO	ND NA A T	TON DISCLOSURE	Application Number	10/627,195	
11			Filing Date	July 25,2003 _	
SIA	IEME	NT BY APPLICANT	First Named Inventor	William D. Ehringer	
			Group Art Unit		
		e as many sheets as necessary)	Examiner Name		
Page <sup>2</sup> o	f 4		Attorney Docket Number	09799910-0038	
		OTHER ITEMS - NON PATE	ENT LITERATURE DOCUME	NTS	
Examiner Initials*	CiteNo.	Include name of the author (in CAPITA item (book, magazine, journal, serial, spublisher, c			T <sup>2</sup>
	C10	Fedelšová, M., A. Ziegelhöffe	er, E-G. Krause, and A. V	Wallenberger, "Effect	
		of Exogenous Adenosine Triphosphate on the Metabolic State of the			
		Excised Hypothermic Dog He			
	C11	Fraley, R., R. Straubinger, G.	· ·	• 1	
		Papahadjopoulos, "Liposome		-	
		Acid to Cells: Enhanced Effic	•	4	
	-	Composition and Incubation			
	C12	Fremes, S., J. Zhang, R. Furu			:
		Pretreatment for Prolonged C		orac.Cardiovas.	
		Surg., 110(2):293-301 (1995)		. 1	
	C13	Garrett, F., S. Goel, J. Yasul, and R. Koch, "Liposomes fuse with sperm			
		cells and induce activation by		agents," Biochim. Et	•
	014	Biophys. Acta, 1417:77-88 (1999).			
	C14	Guo-Xing, X., X. Xing-Hui, L. Fang-Yu, Z. DeLiang, et al., "Adenosine			
		Triphosphate Liposomes: Encapsulation and Distribution Studies,"			
	C15	Pharmaceut. Res., 7(5)553-55		20 1 01 01	
į	C13	Hirasawa, H., K. Soeda, Y, O		<b>O</b> - 1	
		and ATP-Na <sub>2</sub> Administration			
	C16	Following Renal Ischemia," ( Hochachka, P.W. and P.L. Lu			
	1010	anoxia tolerance in animals,"			
		(2001).	Comp. Diocnem. Phys., 1	rail B, 130:433-439	
	C17	Jahn, R. and T.C. Südhof, "M	Tembrane fusion and evo	extosis " Annu Par	
		Biochem. 68:863-911.	remotane tusion and exc	oyiosis, Annu. Rev.	
	C18	Katori, M. and R. Berne, "Rel	lease of Adenosine from	Anoxic Hearts	
		Relationship to Coronary Flor			
	C19	Klein, H., J. Schaper, St. Pusc			
		myocardial nicotinamide ader			
		from reversible to irreversible			
		Res. Cardiol., 76:612-621 (19			
	C20	Kozubek, A., J. Gubernator, H		asiuk, "Liposomal	
1		drug delivery, a novel approac			
		47(3):639-649 (2000).	,	,	

Approved for use through 10/31/2002. OMB 0651-0031

type a plus sign (+) inside this box ™ U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of info unless it contains a valid OMB control no.

Complete if Known Substitute for form 1449A/PTO 10/627,195 **Application Number** INFORMATION DISCLOSURE July 25,2003 Filing Date STATEMENT BY APPLICANT William D. Ehringer First Named Inventor Group Art Unit (use as many sheets as necessary) **Examiner Name** Page <sup>3</sup>of 4 09799910-0038 Attorney Docket Number OTHER ITEMS - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Examiner CiteNo.  $T^2$ item (book, magazine, journal, serial, symposium, catalog etc.), date, page(s), volume-issue number(s), Initials\* publisher, city and/or country where published. C21 Kristensen, S., "Mechanisms of cell damage and enzyme release," Danish Med. Bull., 41(4):423-433 (1994). McAllister, Jr., H., "Histologic Grading of Cardiac Allograft Rejection: A C22 Quantitative Approach," J. Heart Transplant, 9(3):277-282 (1990). C23 Pagano, R. and J. Weinstein, "Interactions of Liposomes with Mammalian Cells," Ann. Rev. Biophys. Bioeng., 7:435-468 (1978). C24 Palombo, J., J. Bowers, M. Clouse, A. McCullough, et al., "Hepatic utilization of exogenous nucleotide precursors for restoration of ATP after cold ischemia in rats," Amer. J. Clin. Nutr., 57:420-427 (1993). C25 Pearson, M. and G. Rohrmann, "Transfer, Incorporation, and Substitution of Envelope Fusion Proteins among Members of the Baculoviridae, Orthomyxoviridae, and Metaviridae (Insect Retrovirus) Families," J. Virology, 76(11):5301-5304 (2002). C26 Puisieux, F, E. Fattal, M. Lahiani, J. Auger, P. Jouannet, P. Couvreur, and J. Delattre, "Liposomes, an interesting tool to deliver a bioenergetic substrate (ATP) in vitro and in vivo studies," J Drug Target 2:443-448 (1994).C27 Reimer, K., R. Jennings, and M. Hill, "Total Ischemia in Dog Hearts, in Vitro," in "High Energy Phosphate Depletion and Associated Defects in Energy Metabolism, Cell Volume Regulation, and Sarcolemmal Integrity," Circ. Res., 49:901-911 (1981). Schiffelers, R., G. Storm, and I. Bakker-Woudenberg, "Liposome-C28 encapsulated aminoglycosides in pre-clinical and clinical studies," J. Antimicrob. Chemotherap., 48:333-344 (2001). Siegel, N., W. Glazier, I. Chaudry, K. Gaudio, et al., "Enhanced recovery C29 from acute renal failure by the postischemic infusion of adenine nucleotides and magnesium chloride in rats," Kidney Int'l, 17:338-349 Stringham, J. Southard, G. Anderson, and F. Belzer, "Mechanisms of ATP C30 Depletion in the Cold-Stored Heart," Transplantation Proc., 23(5):2437-2438 (1991).



5		(+) inside this box ™ + U.S. Pa U.S. Pa eduction Act of 1995, no persons are required	tent and Trademark Office: U.S.		-003 ERC
Substitu	ite for forn	n 1449A/PTO	Comple	ete if Known	
11150			Application Number	10/627,195	
		TION DISCLOSURE	Filing Date	July 25,2003 _	
SIA	I FIME	NT BY APPLICANT	First Named Inventor	William D. Ehringer	
			Group Art Unit		
		se as many sheets as necessary)	Examiner Name		
Page 4 o	of 4		Attorney Docket Number	09799910-0038	
		OTHER ITEMS - NON PAT	TENT LITERATURE DOCUME	ENTS	
Examiner Initials*	CiteNo.	item (book, magazine, journal, serial,	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	C31	Trigiante, G. and W. Huestis	s, "Selective virus-mediate	ed intracellular	T
		delivery of membrane-imper			
			membrane vesicles," Antiviral Res., 45:211-221 (2000).		
	C32	Whitman, G., R. Kieval, L. V	-	•	
		Relationship between Global	•		l
		Function, Myocardial, Redox			
		Phosphorous-31 Nuclear Magnetic Resonance Study," <i>J. Surg. Res.</i> , 35:332-339 (1983).			
	C33		berg J Stein M Lifschit	tz. "Salvage of	$\vdash$
			Venkatachalam, M., J. Kriesberg, J. Stein, M. Lifschitz, "Salvage of Ischemic Cells by Impermeant Solute and Adenosinetriphosphate," Lab.		
Investig., 49(1):1-3 (1983).					

Examiner	Date	
Signature	Considered	



	en de kononiosa orași i <b>v</b> eri veza e en de ar <b>izăt</b> ă	
是一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个一个		
THE SECTION OF THE PARTY OF THE		,
		174
		. XX
ASSISTANT COMMISSIONER FOR PATENTS		4.4
KINDLY ASSUMESSIONER FOR PATENTS		13
KINDLY ACKNOWLEDGE RECEIPT BY DATE		136
	STAMPING AND RETURNING	* 4
Applicant(s) Changes eval	000 March 1700 1800 March 1700 March 170 Was 1800 March 170 Was 1800 March 170 March 170 March 170 March 170 M	N.
TINO 21	Detries ILIC 7710	4
Title WOVER HOTTING COMPOSITE	PCT/US# 1.6/627/195	الد دا
	一、一、一、一、一、一、一、一、一、一、一、一、一、一、一、一、一、一、一、	空空
Transmittal Letter(s)	The state of the s	d
U Specification Pages	09-799910 0038 (00	3
Tages	10.0038	$^{\prime\prime}\Omega$
U Jotal Claims Pages		193
Pance The Pance	C Fee of \$ Paid by	``\\
El Drawinger	Deposit Acct No. 19-3140	1
Digawings Sheet(s) Formal Information (P.D.)	D.CheckNo.	4
The same of the sa		* 2
DADS	J Amex	- 4
		- 4
D'Assignment Auropassium S		1
DAssignment (w/Recordation Sheet))		
D'Assignment (W/Recordation Sheet))  D'Amendment/Response	Date Malled: NOV. 14 2003	
Detition under 37 (ED) 4005	Date Malled NOV 14 2003	or conduction
Detition under 37 CED Macc		The state of the s
Di Petition under 37 CFR (1) 136(a).	Date Malled NOV 14 2003	A contract of
Discussifient/response	Date Malled NOV 14 2003	Charles with the state of the s
Detition under 37 CFR 1 136(a).  Information Disclosure Statement (case)  Dissue Fee Payment	Date Malled NOV 14 2003	Contract of the Contract of th
Dettlion under 37 CFR () (36(a))  Vinformation Disclosure Statement (exact)  Discussifies Payment	Date Malled NOV 14 2003	Sacrate Annies de la constante
Dettlion under 37 CFR () (36(a))  Vinformation Disclosure Statement (exact)  Discussifies Payment	Date Malled NOV 14 2003	Total Control of the
D Petition under 37 CFR 1 136(a)  Unformation Disclosure Statement (exact) Dissue Fee Payment D Request  D Demand  D Fee Calculation Sheet (in diminically)	Date Malled NOV 14 2003	To the state of th
Detition under 37 CFR 1 136(a).  Information Disclosure Statement (case)  Dissue Fee Payment	Date Malled NOV 14 2003	The state of the s
D Petition under 37 CFR 1 136(a)  Unformation Disclosure Statement (exact) Dissue Fee Payment D Request  D Demand  D Fee Calculation Sheet (in diminically)	Date Malled NOV 14 2003	The state of the s
D Petition under 37 CFR 1 136(a)  Unformation Disclosure Statement (exact) Dissue Fee Payment D Request  D Demand  D Fee Calculation Sheet (in diminically)	Date Malled NOV 14 2003	The state of the s
D Petition under 37 CFR 1 136(a)  Unformation Disclosure Statement (exact) Dissue Fee Payment D Request  D Demand  D Fee Calculation Sheet (in diminically)	Date Malled NOV 14 2003	
D Petition under 37 CFR 1 136(a)  Unformation Disclosure Statement (exact) Dissue Fee Payment D Request  D Demand  D Fee Calculation Sheet (in diminically)	Date Malled NOV 14 2003	
D Petition under 37 CFR 1 136(a)  Unformation Disclosure Statement (exact) Dissue Fee Payment D Request  D Demand  D Fee Calculation Sheet (in diminically)	Date Malled NOV 14 2003	
D Petition under 37 CFR 1 136(a)  Unformation Disclosure Statement (exact) Dissue Fee Payment D Request  D Demand  D Fee Calculation Sheet (in diminically)	Date Malled NOV 14 2003	
D Petition under 37 CFR 1 136(a)  Unformation Disclosure Statement (exact) Dissue Fee Payment D Request  D Demand  D Fee Calculation Sheet (in diminically)	Date Malled NOV 14 2003 Express Mall Not:	
D Petition under 37 CFR 1 136(a)  Unformation Disclosure Statement (exact) Dissue Fee Payment D Request  D Demand  D Fee Calculation Sheet (in diminically)	Date Malled NOV 14 2003	
D Petition under 37 CFR 1 136(a)  Unformation Disclosure Statement (exact) Dissue Fee Payment D Request  D Demand  D Fee Calculation Sheet (in diminically)	Date Malled NOV 14 2003 Express Mall Not:	
D Petition under 37 CFR 1 136(a)  Unformation Disclosure Statement (exact) Dissue Fee Payment D Request  D Demand  D Fee Calculation Sheet (in diminically)	Date Malled NOV 14 2003 Express Mall Not:	